Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 19/20 | 0.62 |
| ▸ | CCR3 | P51677 | 19/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5733479 | 0.83 | CCR3 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL5956722 | 0.83 | HRH1 (0.80) | HRH1CCR3KCNH2 | |
| SCHEMBL5732917 | 0.81 | HRH1 (0.58) | HRH1CCR3KCNH2 | |
| SCHEMBL1808245 | 0.81 | RHOA (0.57) | HRH1CCR3 | |
| SCHEMBL6242779 | 0.80 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL5733983 | 0.80 | HRH1 (0.58) | HRH1CCR3KCNH2 | |
| SCHEMBL5733230 | 0.80 | HRH1 (0.65) | HRH1CCR3KCNH2 | |
| SCHEMBL5191284 | 0.80 | HRH1 (0.65) | HRH1CCR3KCNH2 | |
| SCHEMBL5737033 | 0.79 | HRH1 (0.79) | HRH1CCR3KCNH2 | |
| SCHEMBL4968313 | 0.79 | HRH1 (0.81) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281726-A1 | Piperidine derivatives for the treatment of chemokine or h1 mediated disease state | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | disclosed |
| EP-1611124-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CHEMOKINE OR H1 MEDIATED DISEASE STATE | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085423-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CHEMOKINE OR H1 MEDIATED DISEASE STATE | ASTRAZENECA AB (SE) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281726-A1 | Piperidine derivatives for the treatment of chemokine or h1 mediated disease state | CCR3, CCR1, CCL11 | HRH1 23/4885CCR3 1/4885KCNH2 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.